<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39455727</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The effect of COVID-19 vaccination on symptomatic infection and related symptoms among preterm-born children aged 3-7 years in China.</ArticleTitle><Pagination><StartPage>25384</StartPage><MedlinePgn>25384</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25384</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76609-1</ELocationID><Abstract><AbstractText>Vaccination plays a crucial role in preventing and controlling SARS-CoV-2 infections as well as their associated adverse outcomes. But there is a notable lack of research on the effectiveness of COVID-19 vaccination in children, particularly those young preterm-born children, who are more vulnerable to severe outcomes from SARS-CoV-2 infection. We aimed to determine the effect of vaccination with inactivated vaccines BBIBP-CorV and CoronaVac on symptomatic COVID-19 infection and related symptoms in preterm-born children aged 3-7 years after relaxation of the COVID-19 prevention and control measures in December 2022 in China. We performed a retrospective cohort study involving 242 preterm-born children aged 3-7 years and the data were collected in March 2023. Logistic regression models and modified Poisson regression models combined with entropy balancing were used to explore the associations of vaccination against SARS-CoV-2 with symptomatic COVID-19, specific symptoms, and persistent symptoms one month after recovery from COVID-19. Of the 242 recruited preterm-born children, 156 (64.5%) were vaccinated with inactivated vaccines BBIBP-CorV and CoronaVac. After entropy balancing, the covariates were balanced between the vaccinated and the unvaccinated groups, with standardized mean difference &lt; 0.001. Vaccination with the said SARS-CoV-2 vaccines lowered the risk of developing symptomatic COVID-19 in preterm-born children (risk ratio [RR] = 0.783; 95% confidence interval [CI]: (0.711, 0.861). Likewise, COVID-19 vaccination was associated with a decline in the risk of pneumonia (odds ratio [OR] = 0.318; 95% CI 0.110, 0.913), fever (RR = 0.710; 95% CI 0.635, 0.794), high fever (RR = 0.542; 95% CI 0.297, 0.988), sore throat (OR = 0.304; 95% CI 0.139, 0.664), and persistent symptoms (RR = 0.425; 95% CI 0.182, 0.993). Immunization with inactivated vaccines BBIBP-CorV and CoronaVac provides protection against symptomatic COVID-19 for preterm-born children 3-7 years.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Affiliated Children's Hospital of Xiangya School of Medicine, Hunan Children's Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, 100010, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for Birth defects prevention and control of key technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ning</LastName><ForeName>Jia-Dong</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Jingke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, 100010, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for Birth defects prevention and control of key technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Changgen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, 100010, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for Birth defects prevention and control of key technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Shanghong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, 100010, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for Birth defects prevention and control of key technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Zhichun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, 100010, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for Birth defects prevention and control of key technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Han</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, 100010, China. hant8316@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for Birth defects prevention and control of key technology, Beijing, China. hant8316@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China. hant8316@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Organ Failure Research, Department of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China. lylygdsg@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Qiuping</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, 100010, China. zhjhospital@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Laboratory for Birth defects prevention and control of key technology, Beijing, China. zhjhospital@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Key Laboratory of Pediatric Organ Failure, Beijing, China. zhjhospital@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2024A1515011957 to L.L.</GrantID><Agency>Guangdong Basic and Applied Basic Research Foundation</Agency><Country /></Grant><Grant><GrantID>2021YFC2701702 to Q.L.</GrantID><Agency>the National Key R&amp;amp;D Program of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007234" MajorTopicYN="N">Infant, Premature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047928" MajorTopicYN="N">Premature Birth</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Pediatrics</Keyword><Keyword MajorTopicYN="N">Preterm-born children</Keyword><Keyword MajorTopicYN="N">Symptomatic infection</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39455727</ArticleId><ArticleId IdType="pmc">PMC11511927</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76609-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76609-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biancolella, M. et al. COVID-19 annual update: a narrative review [J]. Hum. Genomics. 17 (1), 68 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10367267</ArticleId><ArticleId IdType="pubmed">37488607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, K. &amp; Li-Kim-Moy J. COVID-19 vaccines in 2023 [J]. Aust Prescr. 46 (3), 60–63 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10665092</ArticleId><ArticleId IdType="pubmed">38053809</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, P. et al. Effectiveness and safety of SARS-CoV-2 vaccines among children and adolescents: a systematic review and Meta-analysis [J]. Vaccines (Basel), 10(3) (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8953823</ArticleId><ArticleId IdType="pubmed">35335053</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto Pereira, S. M. et al. Post-COVID-19 condition at 6 months and COVID-19 vaccination in non-hospitalised children and young people [J]. Arch. Dis. Child. 108 (4), 289–295 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10086284</ArticleId><ArticleId IdType="pubmed">36599625</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein, L. R. et al. Effectiveness of Bivalent mRNA COVID-19 vaccines in preventing SARS-CoV-2 infection in children and adolescents aged 5 to 17 years [J]. Jama. 331 (5), 408–416 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10848053</ArticleId><ArticleId IdType="pubmed">38319331</ArticleId></ArticleIdList></Reference><Reference><Citation>Piechotta, V. et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis[J].The Lancet. Child. Adolesc. Health. 7 (6), 379–391 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10112865</ArticleId><ArticleId IdType="pubmed">37084750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan, Z. et al. Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis. Eur. J. Pediatr. 182 (12), 5235–5244 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37768334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hangzhou Center for Disease Control and Prevention SCfDCaP. One of expert consensus on immunization in children with special state-prematurity and vaccination [J]. Chin. J. Appl. Clin. Pediatr. 33 (10), 737–738 (2018).</Citation></Reference><Reference><Citation>Choi, J. H., Choi, S. H. &amp; Yun, K. W. Risk factors for severe COVID-19 in children: a systematic review and Meta-analysis [J]. J. Korean Med. Sci. 37 (5), e35 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822112</ArticleId><ArticleId IdType="pubmed">35132841</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, D. et al. Receipt of COVID-19 vaccine in preterm-born children aged 3–7 in China [J]. Front. Public. Health. 11, 1191941 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10400273</ArticleId><ArticleId IdType="pubmed">37546314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, D. et al. Acceptability of COVID-19 vaccination in Chinese children aged 3–7 years with bronchopulmonary dysplasia [J]. Pediatr. Pulmonol. 58 (5), 1417–1426 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36717531</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, B. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial [J]. Lancet Infect. Dis. 21 (12), 1645–1653 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238449</ArticleId><ArticleId IdType="pubmed">34197764</ArticleId></ArticleIdList></Reference><Reference><Citation>Innovation NCfST. China’s inactivated COVID-19 vaccine has been officially approved for use in people aged 3–17 years. Preprint at (2021). http://www.ncsti.gov.cn/kjdt/ztbd/zyq/zxxx/202107/t20210718_36885.html.</Citation></Reference><Reference><Citation>CK, G. Chinese government: striving to complete the full vaccination of non-contraindication population aged 3 to 11 years by the end of December. Preprint at https://baijiahao.baidu.com/s?id=1715043532185356789&amp;wfr=spider&amp;for=pc (2021).</Citation></Reference><Reference><Citation>website, H. C. Notice on Further Optimizing and Implementing COVID-19 Prevention and Control Measures. https://www.gov.cn/xinwen/2022-12/07/content_5730443.htm (2022).</Citation></Reference><Reference><Citation>J H. Entropy balancing for causal effects: a multivariate reweighing method to produce balanced samples in observational studies [J]. Political Anal. 20(1), 25–46 (2012).</Citation></Reference><Reference><Citation>Austin, P. C. S. E. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies [J]. Stat. Med. 34 (28), 3661–3679 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626409</ArticleId><ArticleId IdType="pubmed">26238958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, W. et al. Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification [J]. BMC Med. Res. Methodol. 18 (1), 63 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013902</ArticleId><ArticleId IdType="pubmed">29929477</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, G. A modified poisson regression approach to prospective studies with binary data [J]. Am. J. Epidemiol. 159 (7), 702–706 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15033648</ArticleId></ArticleIdList></Reference><Reference><Citation>ifeng.com. 95% of people aged 3–17 have been fully vaccinated against COVID-19 in China. Preprint at (2022). https://finance.ifeng.com/c/8H22My8CI2S.</Citation></Reference><Reference><Citation>Tian, C. et al. Influenza vaccination coverage among US children from 2004/2005 to 2015/2016 [J]. J. Public. Health (Oxf). 41 (1), e62–e69 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">29767756</ArticleId></ArticleIdList></Reference><Reference><Citation>Soans, S. et al. Vaccination in preterm and low birth weight infants in India [J]. Hum. Vaccin Immunother. 18 (1), 1–12 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920132</ArticleId><ArticleId IdType="pubmed">33599562</ArticleId></ArticleIdList></Reference><Reference><Citation>China, N. H. C. P. R. Transcript of the press conference of the Joint Prevention and Control Mechanism of the State Council on January 15, Preprint at (2022). http://www.nhc.gov.cn/xcs/yqfkdt/202201/956b9a4d566546d7966d5cf93641bd2a.shtml (2022).</Citation></Reference><Reference><Citation>Province TPsGoH. The cumulative coverage rate of the first dose of COVID-19 vaccine among people aged 3 to 11 years in our province has reached 97.76%. Preprint at (2022). https://www.hainan.gov.cn/hainan/yqfkzzzzxxx/202202/7394493b54aa4800826fc8e459a0633c.shtml.</Citation></Reference><Reference><Citation>Zheng, Y. J. et al. Expert’s consensus on severe acute respiratory syndrome coronavirus-2 vaccination of children [J]. Chin. J. Appl. Clin. Pediatr. 36 (18), 1361–1367 (2021).</Citation></Reference><Reference><Citation>Thakkar, K. et al. Impact of vaccination and non-pharmacological interventions on COVID-19: a review of simulation modeling studies in Asia [J]. Front. Public. Health. 11, 1252719 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10560858</ArticleId><ArticleId IdType="pubmed">37818298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy, R. COVID-19 vaccines for optimizing immunity in the Upper respiratory tract [J]. Viruses. 15(11) (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10674974</ArticleId><ArticleId IdType="pubmed">38005881</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck, R. W. et al. Safety, Immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents [J]. N Engl. J. Med. 385 (3), 239–250 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski, D. M. &amp; De Serres, G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine [J]. N Engl. J. Med. 384 (16), 1576–1577 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33596348</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, M. et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France [J]. Jama. 327 (3), 281–283 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689418</ArticleId><ArticleId IdType="pubmed">34928295</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, T. H. et al. Effectiveness of COVID-19 vaccination against multisystem inflammatory syndrome in children: a systematic review and meta-analysis [J]. J. Microbiol. Immunol. Infect.56 (6), 1299–1300 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37673732</ArticleId></ArticleIdList></Reference><Reference><Citation>Boufidou, F. et al. SARS-CoV-2 reinfections and Long COVID in the Post-omicron phase of the pandemic [J]. Int. J. Mol. Sci. 24(16). (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10454552</ArticleId><ArticleId IdType="pubmed">37629143</ArticleId></ArticleIdList></Reference><Reference><Citation>Català, M. et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia [J]. Lancet Respir Med. 12 (3), 225–236 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantarabenjakul, W. et al. Global COVID-19 vaccination in infants and children: effectiveness, Safety, and challenges [J]. Asian Pac. J. Allergy Immunol. 41 (4), 292–303 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37874316</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell, A. A. et al. Current state of COVID-19 in children: 4 years on [J]. J. Infect. 88 (5), 106134 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38432584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastrolia, M. V. et al. Clinical syndromes related to SARS-CoV-2 infection and vaccination in Pediatric Age: a narrative review [J]. Med. (Kaunas), 59(11) (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10673592</ArticleId><ArticleId IdType="pubmed">38004076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets, L. et al. Underlying Medical conditions Associated with severe COVID-19 illness among children [J]. JAMA Netw. Open. 4 (6), e2111182 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185607</ArticleId><ArticleId IdType="pubmed">34097050</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, T. et al. Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study [J]. Lancet Respir Med. 10 (2), 191–198 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631918</ArticleId><ArticleId IdType="pubmed">34861180</ArticleId></ArticleIdList></Reference><Reference><Citation>Akahata, W. et al. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: a randomized, observer-blind phase 1 study [J]. Cell. Rep. Med. 4 (8), 101134 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10439244</ArticleId><ArticleId IdType="pubmed">37586325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappini, E. et al. Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian society of neonatology [J]. Ital. J. Pediatr. 45 (1), 145 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6862761</ArticleId><ArticleId IdType="pubmed">31744514</ArticleId></ArticleIdList></Reference><Reference><Citation>Omeñaca, F. et al. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines [J]. Pediatr. Infect. Dis. J. 30 (11), e216–e224 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21747321</ArticleId></ArticleIdList></Reference><Reference><Citation>Knuf, M. et al. Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: a systematic literature review [J]. Hum. Vaccin Immunother. 19 (1), 2191575 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10120554</ArticleId><ArticleId IdType="pubmed">37076111</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoto, P. D. et al. Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: a systematic review and meta-analysis [J]. Hum. Vaccin Immunother. 19 (1), 2214495 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10294753</ArticleId><ArticleId IdType="pubmed">37277959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad, S. M. et al. The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis [J]. Pediatr. Rheumatol. Online J. 21 (1), 80 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10405572</ArticleId><ArticleId IdType="pubmed">37550719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, F. et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections in children [J]. Chin. J. Infect. Dis. 41 (01), 58–63 (2023).</Citation></Reference><Reference><Citation>Lan, Z. et al. Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis [J]. Eur. J. Pediatr. 182 (12), 5235–5244 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37768334</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study [J]. Lancet. 398(10309), 1407–1416 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489881</ArticleId><ArticleId IdType="pubmed">34619098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandnes, R. et al. Parental stress and mental health outcomes following very preterm birth: a systematic review of recent findings [J]. J. Affect. Disord. 355, 513–525 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38556094</ArticleId></ArticleIdList></Reference><Reference><Citation>Staver, M. A., Moore, T. A. &amp; Hanna, K. M. An integrative review of maternal distress during neonatal intensive care hospitalization [J]. Arch. Womens Ment Health. 24 (2), 217–229 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32851469</ArticleId></ArticleIdList></Reference><Reference><Citation>Guittard, C. et al. Effect of tactile and/or kinesthetic stimulation therapy of preterm infants on their parents’ anxiety and depressive symptoms: a systematic review [J]. BMC Psychol. 12 (1), 3 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10759426</ArticleId><ArticleId IdType="pubmed">38167522</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin, P. Immune responses to SARS-CoV-2 infection and vaccination in children [J]. Semin Immunol. 69, 101794 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10281229</ArticleId><ArticleId IdType="pubmed">37536147</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito, S. et al. True prevalence of long COVID in children: a narrative review [J]. Front. Microbiol. 14, 1225952 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10543413</ArticleId><ArticleId IdType="pubmed">37789860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>